SYNCHRONIZE-1 is the registrational Phase 3 obesity trial of survodutide, the glucagon/GLP-1 dual agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. The trial enrolled adults with obesity or overweight without type 2 diabetes and tested the dual-agonist hypothesis that adding glucagon receptor activity to GLP-1 should produce more weight loss and better liver-fat effects than GLP-1 alone.
The topline released April 28, 2026 met both co-primary endpoints. Survodutide produced up to 16.6% mean weight loss at 76 weeks versus 3.2% on placebo (p<0.0001), and up to 85.1% of treated adults reached at least 5% weight loss. The full data presented at ADA 2026 added body-composition and liver-fat analyses showing reductions driven largely by fat-tissue loss rather than lean mass. Survodutide carries FDA Fast Track and Breakthrough Therapy designations, and SYNCHRONIZE-1 anchors the obesity filing alongside the LIVERAGE Phase 3 program in MASH and the broader survodutide diabetes pipeline.
Stories here cover SYNCHRONIZE-1 readouts, the survodutide regulatory path, and the wider glucagon/GLP-1 dual-agonist field. See #survodutide, #boehringer-ingelheim, and #glp-1-glucagon for adjacent threads.
Boehringer Ingelheim and Zealand Pharma presented a pre-specified body-composition analysis of SYNCHRONIZE-1 at ADA's Monday session: survodutide produced up to 34% relative reduction in visceral fat and 63.1% reduction in liver fat from baseline at 76 weeks, while limiting lean-mass loss. The company also disclosed SYNCHRONIZE-MASLD results: 6 of 10 patients with MASLD reached liver-fat normalization at 48 weeks. The body-composition story is Boehringer's response to a 16.6% headline weight number that analysts had called less competitive than Lilly's.
Boehringer Ingelheim and Zealand Pharma presented the full Phase 3 SYNCHRONIZE-1 readout for survodutide, the glucagon/GLP-1 dual agonist, at ADA 2026. In adults with obesity or overweight without type 2 diabetes, survodutide produced up to 16.6% mean weight loss at 76 weeks versus 3.2% placebo (p<0.0001), with up to 85.1% achieving at least 5% loss. Analyst attention now turns to body composition and liver-fat substudies, with reductions driven largely by fat-tissue loss rather than lean mass.
Full Phase 3 SYNCHRONIZE-1 results for the glucagon/GLP-1 dual agonist survodutide are set for ADA 2026, detailing the obesity readout first toplined in April. In adults with obesity or overweight without type 2 diabetes, survodutide produced up to 16.6% mean weight loss at 76 weeks versus 3.2% on placebo, with up to 85.1% of treated patients losing at least 5% of body weight. The full dataset puts survodutide's glucagon component, which adds energy expenditure and liver-fat effects, in front of the field that gathers in New Orleans.
Boehringer Ingelheim and Zealand Pharma announced positive topline results from the Phase 3 SYNCHRONIZE-1 trial of survodutide (BI 456906), a glucagon/GLP-1 dual agonist, in adults with obesity or overweight without type 2 diabetes. Adults treated with survodutide achieved 16.6% mean weight loss at 76 weeks (efficacy estimand) versus 3.2% placebo (p<0.0001), with up to 85.1% of treated adults achieving ≥5% weight reduction. Up to 39.2 lb (17.8 kg) average weight loss; initial analysis indicates predominantly fat-tissue loss with lean mass contributing only a small proportion. Full data will be presented at ADA 2026 in June.
Boehringer Ingelheim confirmed completion of the 76-week primary endpoint visit for the last participant in Phase 3 SYNCHRONIZE-1. Topline data expected H1 2026 — making it one of the year's most anticipated obesity readouts. Survodutide is a glucagon/GLP-1 dual agonist co-developed with Zealand Pharma. The comprehensive SYNCHRONIZE program also includes SYNCHRONIZE-CVOT (cardiovascular outcomes, fully enrolled). All key trials are scheduled to read out at scientific meetings throughout 2026, potentially paving the way for regulatory submission as the third major obesity GLP-1-class drug after semaglutide and tirzepatide.